The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02174731




Registration number
NCT02174731
Ethics application status
Date submitted
24/06/2014
Date registered
25/06/2014
Date last updated
16/12/2019

Titles & IDs
Public title
Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.
Scientific title
A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients
Secondary ID [1] 0 0
D5740C00002
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anemia 0 0
Condition category
Condition code
Blood 0 0 0 0
Anaemia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Roxadustat
Treatment: Drugs - Epoetin alfa

Experimental: Roxadustat -

Active Comparator: Epoetin alfa -


Treatment: Drugs: Roxadustat
Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.

Treatment: Drugs: Epoetin alfa
Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 - Baseline Hb was defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to the participants mean level from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation Analysis of Covariance (ANCOVA). Baseline Hb was used as a covariate and treatment group, cardiovascular (CV) history, geographic region and dialysis duration as fixed effects. The adjusted least squares (LS) mean estimates of change from baseline during Week 28 to Week 52 are presented.
Timepoint [1] 0 0
Baseline (Day 1, Week 0), Week 28 to 52
Secondary outcome [1] 0 0
Change in Hb From Baseline to the Mean Level During the Evaluation Period (Week 28 to Week 36) Without Having Received Rescue Therapy Within 6 Weeks Prior to and During the 8-Week Evaluation Period - Baseline Hb was defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to the participants mean level from Week 28 to Week 36,without having received rescue therapy within 6 weeks prior to and during this 8 week evaluation period was analysed using Mixed Model of Repeated Measures (MMRM). Baseline Hb was used as a covariate and treatment group, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline during Week 28 to Week 36 are presented for participants that did not receive rescue therapy within 6 weeks prior to and during this 8-week evaluation period.
Timepoint [1] 0 0
Baseline (Day 1, Week 0), Week 28 to 36
Secondary outcome [2] 0 0
Proportion of Total Time of Hb Within the Interval of >=10 g/dL From Week 28 to Week 52 - The proportion of total time was computed as follows: For each participant, the recorded Hb values were first linearly interpolated between measurements. The time this interpolated curve was >=10 g/dL was computed and subsequently divided by the time between the measurements from Week 28 to Week 52. The difference between roxadustat and epoetin alfa were compared using ANCOVA. Baseline Hb was used as a covariate and the treatment groups, CV history, geographic region and dialysis duration as fixed effects.
Timepoint [2] 0 0
Week 28 to 52
Secondary outcome [3] 0 0
Proportion of Total Time of Hb Within the Interval of 10 to 12 g/dL From Week 28 to Week 52 - The proportion of total time was computed as follows: For each participant, the recorded Hb values were first linearly interpolated between measurements. The time this interpolated curve was within 10-12 g/dL was computed and subsequently divided by the time between the measurement from Week 28 to 52. The difference between roxadustat and epoetin alfa were compared using ANCOVA. Baseline Hb was used as a covariate and the treatment groups, CV history, geographic region and dialysis duration as fixed effects.
Timepoint [3] 0 0
Week 28 to 52
Secondary outcome [4] 0 0
Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24 - Baseline LDL was defined as the last result obtained prior to randomization. Mean changes in LDL cholesterol from baseline to Week 24 was analysed using ANCOVA. Baseline Hb and baseline LDL were used as covariates and treatment groups, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline to Week 24 are presented.
Timepoint [4] 0 0
Baseline (Day 1, Week 0) to Week 24
Secondary outcome [5] 0 0
Mean Change in Hb From Baseline to the Participant's Mean Level Between Week 28 to Week 52 in Participants With Baseline High-Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN) - Baseline hsCRP was quantified from stored biomarker samples obtained at randomization. Baseline Hb is defined as the mean of the three last central laboratory Hb values from the screening and randomization visits. Changes in Hb from baseline to mean value during Weeks 28 to 52 in participants with baseline hsCRP >ULN was analyzed using a MAR based multiple imputation ANCOVA. Baseline Hb was used as a covariate and treatment group, CV history, geographic region and dialysis duration as fixed effects. The adjusted LS mean estimates of change from baseline during Week 28 to Week 52 are presented.
Timepoint [5] 0 0
Baseline (Day 1, Week 0), Week 28 to 52
Secondary outcome [6] 0 0
Mean Monthly IV Iron Use From Week 36 to End of Study (EOS) - Oral iron supplementation was allowed for both treatment groups without restriction. Oral iron was recommended for dietary supplementation to support erythropoiesis and as the first line treatment for prevention and treatment of iron deficiency, unless the participant was intolerant to this route of treatment. In participants receiving roxadustat, the Investigator was allowed to initiate the use of an approved IV iron supplement if a participant's Hb value had not sufficiently responded to 2 or more dose increases of the IP, and ferritin <100 nanogram per milliliter (ng/mL) or transferrin saturation (TSAT) <20%. IP treatment was allowed to continue during IV iron administration. Discontinuation of IV iron supplementation was recommended once the participant was no longer considered to be iron deficient (ferritin >100 ng/mL and TSAT >20%).
Timepoint [6] 0 0
Week 36 to EOS (4 weeks after the treatment period)
Secondary outcome [7] 0 0
Time-To-First Administration of RBC Transfusion as Rescue Therapy - Time-to-first RBC transfusion as rescue therapy was calculated as (date of first occurrence of any RBC transfusion as rescue therapy, or date of censoring if no event had occurred) - (date of first dose of IP) + 1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.
Timepoint [7] 0 0
Baseline (Day 1, Week 0) up to EOS (4 weeks after the treatment period)

Eligibility
Key inclusion criteria
Inclusion criteria:

1. Provision of Informed Consent prior to any study specific procedures

2. Age =18 years at screening visit 1

3. Previous versions of the protocol prior to US amendment ver 6.0 and outside of US
amendment ver 7.0:

Receiving or initiating hemodialysis or peritoneal dialysis for treatment of native
kidney end-stage renal disease (ESRD) at least 30 days prior to visit 1. Patients
treated with hemodialysis must have access consisting of an arteriovenous fistula, AV
graft, or tunneled (permanent) catheter. Patients on peritoneal dialysis must have a
functioning peritoneal dialysis catheter in place.

Starting with US amendment ver. 6.0 and outside of US amendment ver 7.0 (changed to
recruit incident dialysis patients only):

Receiving or initiating hemodialysis or peritoneal dialysis for treatment of native
kidney end-stage renal disease (ESRD) for a minimum of 2 weeks and a maximum of 4
months prior to randomization. Patients treated with hemodialysis must have access
consisting of an arteriovenous fistula, AV graft, or tunneled (permanent) catheter.
Patients on peritoneal dialysis must have a functioning peritoneal dialysis catheter
in place.

4. Two central laboratory Hb values during the screening period, obtained at least 7 days
apart, must be <12 g/dL in patients currently treated with an erythropoietin analogue
or <10 g/dL in patients not currently treated with an erythropoietin analogue.
Patients are considered not currently treated if they have not received either
Mircera® for at least 8 weeks or any other erythropoietin analogue for at least 4
weeks prior to visit 1.

5. Ferritin =100 ng/mL at randomization (obtained from screening visit)

6. TSAT =20% at randomization (obtained from screening visit)

7. Serum folate level = lower limit of normal (LLN) at randomization (obtained from
screening visit)

8. Serum vitamin B12 level = LLN at randomization (obtained from screening visit)

9. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =3x upper limit of
normal (ULN), and total bilirubin (Tbili) =1.5 x ULN at randomization (obtained from
screening visit)

10. Body weight 45 to 160 kg (prescribed dry weight)
Minimum age
18 Years
Maximum age
130 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
staff and/or staff at the study site)

2. Previous randomisation in the present study

3. New York Heart Association Class III or IV congestive heart failure at enrolment

4. Myocardial infarction, acute coronary syndrome, stroke, seizure or a
thrombotic/thromboembolic event (e.g., deep vein thrombosis or pulmonary embolism)
within 12 weeks prior to randomization

5. History of chronic liver disease (e.g., chronic infectious hepatitis, chronic
auto-immune liver disease, cirrhosis or fibrosis of the liver)

6. Known hereditary hematologic disease such as thalassemia, sickle cell anemia, a
history of pure red cell aplasia or other known causes for anemia other than CKD

7. Known and untreated retinal vein occlusion or known and untreated proliferative
diabetic retinopathy (risk for retinal vein thrombosis)

8. Diagnosis or suspicion (e.g. complex kidney cyst of Bosniak Category IIF, III or IV)
of renal cell carcinoma on renal ultrasound (or other imaging procedure e.g. CT scan
or MRI) conducted at screening or within 12 weeks prior to randomization.

9. Uncontrolled hypertension at the time of randomization (defined as systolic BP =180
mmHg or diastolic BP =100 mmHg on repeated measurement post-dialysis in hemodialysis
patients or at any time in peritoneal dialysis patients), contraindication to epoetin
alfa treatment (e.g., pure red cell aplasia, hypersensitivity or know inability to
tolerate epoetin alfa)

10. History of prostate cancer, breast cancer or any other malignancy, except the
following: cancers determined to be cured or in remission for =5 years, curatively
resected basal cell or squamous cell skin cancers, cervical cancer in situ or resected
colonic polyps.

11. Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B
surface antigen (HBsAg) or anti-hepatitis C virus antibody (anti-HCV Ab)

12. Chronic inflammatory diseases such as rheumatoid arthritis, SLE, ankylosing
spondylitis, psoriatic arthritis or inflammatory bowel disease that is determined to
be the principal cause of anemia

13. Known hemosiderosis, hemochromatosis or hypercoagulable condition

14. Any prior organ transplant with the exception of an autologous renal transplant or a
renal transplant that was subsequently removed ("explanted") or scheduled organ
transplantation date

15. Any red blood cell (RBC) transfusion during the screening period

16. Any current condition leading to active significant blood loss

17. Any prior treatment with roxadustat or a hypoxia-inducible factor prolyl hydroxylase
inhibitor (HIF-PHI)

18. Has received another new chemical entity (defined as a compound which has not been
approved for marketing) or has participated in any other clinical study that included
drug treatment within the month preceding the first administration of IP in this
study. (Note: patients consented and screened, but not randomized in this study or a
previous study are not excluded)

19. History of alcohol or drug abuse within 2 years prior to randomization

20. Females of childbearing potential, unless using contraception as detailed in the
protocol or sexual abstinence (see Section 3.8)

21. Pregnant or breastfeeding females

22. Known allergy to the investigational product or any of its ingredients

23. Any medical condition, including active, clinically significant infection, that in the
opinion of the investigator or Sponsor may pose a safety risk to a patient in this
study, which may confound efficacy or safety assessment, or may interfere with study
participation

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Camperdown
Recruitment hospital [2] 0 0
Research Site - Clayton
Recruitment hospital [3] 0 0
Research Site - Concord
Recruitment hospital [4] 0 0
Research Site - Launceston
Recruitment hospital [5] 0 0
Research Site - Prahan
Recruitment hospital [6] 0 0
Research Site - St Leonards
Recruitment hospital [7] 0 0
Research Site - Wahroonga
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
2139 - Concord
Recruitment postcode(s) [4] 0 0
7250 - Launceston
Recruitment postcode(s) [5] 0 0
3004 - Prahan
Recruitment postcode(s) [6] 0 0
2065 - St Leonards
Recruitment postcode(s) [7] 0 0
2076 - Wahroonga
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Mississippi
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Nevada
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
Rhode Island
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
West Virginia
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Botevgrad
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Dupnitsa
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Gotse Delchev
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Haskovo
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Razlog
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Samokov
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Sandanski
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Shumen
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Silistra
Country [34] 0 0
Bulgaria
State/province [34] 0 0
Sliven
Country [35] 0 0
Bulgaria
State/province [35] 0 0
Smolyan
Country [36] 0 0
Bulgaria
State/province [36] 0 0
Yambol
Country [37] 0 0
Canada
State/province [37] 0 0
Alberta
Country [38] 0 0
Canada
State/province [38] 0 0
British Columbia
Country [39] 0 0
Canada
State/province [39] 0 0
New Brunswick
Country [40] 0 0
Canada
State/province [40] 0 0
Nova Scotia
Country [41] 0 0
Canada
State/province [41] 0 0
Ontario
Country [42] 0 0
Canada
State/province [42] 0 0
Quebec
Country [43] 0 0
Czechia
State/province [43] 0 0
Brno
Country [44] 0 0
Czechia
State/province [44] 0 0
Praha 4
Country [45] 0 0
Czechia
State/province [45] 0 0
Praha
Country [46] 0 0
Czechia
State/province [46] 0 0
Rychnov nad Kneznou
Country [47] 0 0
Czechia
State/province [47] 0 0
Slany
Country [48] 0 0
Czechia
State/province [48] 0 0
Tabor
Country [49] 0 0
Czechia
State/province [49] 0 0
Usti nad Labem
Country [50] 0 0
Hungary
State/province [50] 0 0
Ajka
Country [51] 0 0
Hungary
State/province [51] 0 0
Budapest
Country [52] 0 0
Hungary
State/province [52] 0 0
Debrecen
Country [53] 0 0
Hungary
State/province [53] 0 0
Miskolc
Country [54] 0 0
Hungary
State/province [54] 0 0
Nagykanizsa
Country [55] 0 0
Hungary
State/province [55] 0 0
Székesfehérvár
Country [56] 0 0
Hungary
State/province [56] 0 0
Tatabánya
Country [57] 0 0
India
State/province [57] 0 0
Chennai
Country [58] 0 0
India
State/province [58] 0 0
Ghaziabad NCR
Country [59] 0 0
India
State/province [59] 0 0
Hyderabad
Country [60] 0 0
India
State/province [60] 0 0
Kolkatta
Country [61] 0 0
India
State/province [61] 0 0
Lucknow
Country [62] 0 0
India
State/province [62] 0 0
Maharashtra
Country [63] 0 0
India
State/province [63] 0 0
Mumbai
Country [64] 0 0
India
State/province [64] 0 0
Mysore
Country [65] 0 0
India
State/province [65] 0 0
Nadiad
Country [66] 0 0
India
State/province [66] 0 0
New Delhi
Country [67] 0 0
India
State/province [67] 0 0
Pune
Country [68] 0 0
India
State/province [68] 0 0
Vellore
Country [69] 0 0
India
State/province [69] 0 0
Vijayawada
Country [70] 0 0
Mexico
State/province [70] 0 0
Aguascalientes
Country [71] 0 0
Mexico
State/province [71] 0 0
Guadalajara
Country [72] 0 0
Mexico
State/province [72] 0 0
Mexico
Country [73] 0 0
Mexico
State/province [73] 0 0
Veracruz
Country [74] 0 0
Peru
State/province [74] 0 0
Lima
Country [75] 0 0
Philippines
State/province [75] 0 0
Cebu City
Country [76] 0 0
Philippines
State/province [76] 0 0
Iloilo City
Country [77] 0 0
Philippines
State/province [77] 0 0
Iloilo
Country [78] 0 0
Poland
State/province [78] 0 0
Ciechanów
Country [79] 0 0
Poland
State/province [79] 0 0
Katowice
Country [80] 0 0
Poland
State/province [80] 0 0
Konskie
Country [81] 0 0
Poland
State/province [81] 0 0
Pszczyna
Country [82] 0 0
Poland
State/province [82] 0 0
Suwalki
Country [83] 0 0
Poland
State/province [83] 0 0
Tarnów
Country [84] 0 0
Poland
State/province [84] 0 0
Warszawa
Country [85] 0 0
Poland
State/province [85] 0 0
Lódz
Country [86] 0 0
Russian Federation
State/province [86] 0 0
Arkhangelsk
Country [87] 0 0
Russian Federation
State/province [87] 0 0
Barnaul
Country [88] 0 0
Russian Federation
State/province [88] 0 0
Irkutsk
Country [89] 0 0
Russian Federation
State/province [89] 0 0
Izhevsk
Country [90] 0 0
Russian Federation
State/province [90] 0 0
Kemerovo
Country [91] 0 0
Russian Federation
State/province [91] 0 0
Moscow
Country [92] 0 0
Russian Federation
State/province [92] 0 0
Nizhny Novgorod
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Penza
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Perm
Country [95] 0 0
Russian Federation
State/province [95] 0 0
Pyatigorsk
Country [96] 0 0
Russian Federation
State/province [96] 0 0
Ryazan
Country [97] 0 0
Russian Federation
State/province [97] 0 0
Saint Petersburg
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Ufa
Country [99] 0 0
Slovakia
State/province [99] 0 0
Banska Bystrica
Country [100] 0 0
Slovakia
State/province [100] 0 0
Bratislava
Country [101] 0 0
Slovakia
State/province [101] 0 0
Kosice
Country [102] 0 0
Slovakia
State/province [102] 0 0
Kralovsky Chlmec
Country [103] 0 0
Slovakia
State/province [103] 0 0
Nove Zamky
Country [104] 0 0
Slovakia
State/province [104] 0 0
Zvolen
Country [105] 0 0
Spain
State/province [105] 0 0
Almería
Country [106] 0 0
Spain
State/province [106] 0 0
Barcelona
Country [107] 0 0
Spain
State/province [107] 0 0
Granollers (Barcelona)
Country [108] 0 0
Spain
State/province [108] 0 0
Málaga
Country [109] 0 0
Spain
State/province [109] 0 0
Sevilla
Country [110] 0 0
Spain
State/province [110] 0 0
Tarragona
Country [111] 0 0
Spain
State/province [111] 0 0
Valencia
Country [112] 0 0
Sweden
State/province [112] 0 0
Karlstad
Country [113] 0 0
Sweden
State/province [113] 0 0
Stockholm
Country [114] 0 0
Sweden
State/province [114] 0 0
Uppsala
Country [115] 0 0
Sweden
State/province [115] 0 0
Västerås
Country [116] 0 0
Thailand
State/province [116] 0 0
Bangkok
Country [117] 0 0
Ukraine
State/province [117] 0 0
Chernivtsi
Country [118] 0 0
Ukraine
State/province [118] 0 0
Dnipro
Country [119] 0 0
Ukraine
State/province [119] 0 0
Ivano-Frankivsk
Country [120] 0 0
Ukraine
State/province [120] 0 0
Kyiv
Country [121] 0 0
Ukraine
State/province [121] 0 0
Odesa
Country [122] 0 0
Ukraine
State/province [122] 0 0
Poltava
Country [123] 0 0
Ukraine
State/province [123] 0 0
Ternopil
Country [124] 0 0
Ukraine
State/province [124] 0 0
Uzhhorod
Country [125] 0 0
Ukraine
State/province [125] 0 0
Vinnytsia
Country [126] 0 0
Ukraine
State/province [126] 0 0
Zaporizhzhya
Country [127] 0 0
Vietnam
State/province [127] 0 0
Can Tho
Country [128] 0 0
Vietnam
State/province [128] 0 0
Hanoi
Country [129] 0 0
Vietnam
State/province [129] 0 0
Hochiminh
Country [130] 0 0
Vietnam
State/province [130] 0 0
Hue

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
FibroGen
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of roxadustat compared to
epoetin alfa for the treatment of anemia in chronic kidney disease patients on dialysis.
Trial website
https://clinicaltrials.gov/show/NCT02174731
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Steven Fishbane, MD
Address 0 0
Chief Division of Kidney Diseases and Hypertension, North Shore University Hospital, Great Neck, NY, USA
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications